trending Market Intelligence /marketintelligence/en/news-insights/trending/_Y4jVJrzT5ykIBq3XUJnnA2 content esgSubNav
In This List

Bayer's lymphoma drug meets primary endpoint in phase 2 trial

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Bayer's lymphoma drug meets primary endpoint in phase 2 trial

Bayer AG's phase 2 trial evaluating the investigational copanlisib treatment for relapsed or refractory indolent non-Hodgkin lymphoma, or iNHL, met its primary endpoint.

Under the study, patients showed an objective response rate of 59.2%, with a complete response rate of 12% and a median duration of response of more than 98 weeks or 687 days, Bayer said in a news release. The full analysis set comprised 142 patients, 141 of which had iNHL.

Non-Hodgkin lymphoma is a type of blood cancer.